Studies have shown that formononetin combination therapy reverses adriamycin-induced epithelial-mesenchymal transformation (EMT) of tumor cells and prevents EMT by inhibiting HDAC5, thereby enhancing the therapeutic effect of adriamycin on GBM cells. The gene discussed is HDAC5; the disease is neoplasm.